Favorable Press Coverage Somewhat Unlikely to Affect Dimension Therapeutics (DMTX) Share Price

Media stories about Dimension Therapeutics (NASDAQ:DMTX) have been trending positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dimension Therapeutics earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.3875747367862 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Dimension Therapeutics (DMTX) traded down $0.03 during midday trading on Thursday, hitting $5.95. 27,700 shares of the stock traded hands, compared to its average volume of 150,214. The firm has a market capitalization of $149.06 and a price-to-earnings ratio of -2.67. Dimension Therapeutics has a 1-year low of $1.05 and a 1-year high of $6.10. The company has a current ratio of 2.01, a quick ratio of 3.33 and a debt-to-equity ratio of 0.14.

Dimension Therapeutics (NASDAQ:DMTX) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.20). Dimension Therapeutics had a negative return on equity of 240.95% and a negative net margin of 378.28%. The firm had revenue of $4.48 million for the quarter. equities analysts expect that Dimension Therapeutics will post -1.99 EPS for the current fiscal year.

Several research firms recently commented on DMTX. ValuEngine upgraded shares of Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 30th. Wells Fargo & Co lowered shares of Dimension Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $9.00 to $6.00 in a research report on Tuesday, October 3rd. Citigroup upgraded shares of Dimension Therapeutics from a “sell” rating to a “neutral” rating and lifted their target price for the company from $5.50 to $6.00 in a research report on Tuesday, October 3rd. Finally, Chardan Capital reiterated a “buy” rating on shares of Dimension Therapeutics in a research report on Friday, December 22nd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $5.08.

COPYRIGHT VIOLATION NOTICE: “Favorable Press Coverage Somewhat Unlikely to Affect Dimension Therapeutics (DMTX) Share Price” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3144602/favorable-press-coverage-somewhat-unlikely-to-affect-dimension-therapeutics-dmtx-share-price.html.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Insider Buying and Selling by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.